Kornimate/medical-research-clean huggingface dataset:
chloride high level of resuscitation infusion chloride high level of resuscitation infusion delivered evaluation

Conditions: Shock; Critical Illness

Summary: the purpose of this study is to determine whether intravenous fluid management using lower chloride solutions (hartmann's solutions and plasmalyte®) will result in better outcome when compared to management using high chloride solutions (0.9% saline and gelofusine®).

this is a prospective, controlled, before-and-after study. the baseline pre-intervention period will include collection of data while doctors and nurses are unaware that such collection is taking place. during this time, high chloride fluids (saline, gelofusine, 4% albumin) will continue to be used according to standard practice with an estimated 30,000 liters of saline as well as 2,000 bottles of gelofusine® being consumed. following a wash out period of education and preparation, there will be a complete shift to a working environment where use of saline, gelofusine and any other fluids with a high chloride level (\>110 mmol/l)will be restricted and substituted with fluids of lower chloride concentration similar to blood; either hartmann's solution or plasmalyte® or 20% albumin. the study will compare a 6 month control period (before) and a six month intervention period (after).

Eligibility criteria:
inclusion criteria: * all intensive care unit (icu) admissions at austin hospital * all emergency department (ed) admissions at austin hospital * all operations at operating theatre (ot) with hospital stay of more than 48 hours exclusion criteria: nil

Keywords: chloride acidosis
olfactory stimulation for very low birth weight infants

Conditions: Very Low Birth Weight Infant

Summary: this is a rct study examining whether odor administration to mothers of very low birth weight infants promotes stabilization of vital signs compared with common nursing care. this study used breast milk olfactory stimuli familiar and liked by premature infants to understand the effects of olfactory stimuli on the physiological indicators of very low birth weight infants, the effect on the time of complete enteral nutrition, and the effects on growth and development of very low birth weight infants.

fluctuations in vital signs of very low birth weight infants may lead to poor prognosis. research objectives: to evaluate the effect of olfactory stimulation of breast milk on the stability of physiological indexes of very low birth weight infants subjects: very low birth weight infants whose gestational age are less than 32 weeks.

Eligibility criteria:
inclusion criteria: * gestational age at birth \<32 weeks; * birth weight \< 1500 g; * admission to hospital within 24 hours after birth; * mother can provide breast milk exclusion criteria: * severe congenital malformations; * complicated congenital heart disease; * congenital gastrointestinal disease; * intraventricular hemorrhage

Keywords: olfactory stimulation heart rate oxygen saturation respiratory rate
effect of modified air-pulse stimulation on tracheotomised patients with dysphagia after stroke

Conditions: Stroke

Summary: to evaluate the efficacy of flexible endoscopy-mediated modified air-pulse stimulation in restoring of swallowing function in this group of patients.forty-two subacute stroke patients with tracheotomy and dysphagia need to be recruited and divided into a control group of 21 cases and a trial group of 21 cases. on the basis of receiving personalized swallowing rehabilitation training, the control group received traditional air-pulse stimulation therapy, while the trial group received modified air-pulse stimulation therapy mediated by flexible endoscopy. murray secretion scale (mss), penetration-aspiration scale (pas) and spontaneous swallowing frequency were used to assess dysphagia. moreover, clinical pulmonary infection score (cpis) was used for evaluating the degree of pneumonia, hemoglobin(hb) and serum prealbumin (pab) were used to assess the nutritional status of patients.


Eligibility criteria:
inclusion criteria: * patients who met the diagnostic criteria for stroke formulated in the 4th national academic conference on cerebrovascular disease; * patients with relatively stable vital signs, with a nihss score of 21 points; * patients with tracheotomy accompanied by dysphagia; * no previous history of dysphagia; * age ≥ 30 years and ≤80 years; * informed consent signed by the patient and his family. exclusion criteria: * patients with medullary haemorrhage/infarction; * patients that experienced cerebral hernia and recurrent stroke; * patients with unstable arrhythmia, fever, infection, severe restlessness and inability to cooperate with treatment; * patients with gastro-oesophageal reflux, bilateral paralysis of the vocal cord, laryngopharyngeal stenosis/haemorrhage/tumour; * patients in which there was an inability to accurately locate epiglottis and arytenoid cartilage due to throat disease; * patients with a history of epilepsy or risk of seizures.
a study to evaluate the effects for midface improvement when pairing a biostimulator with a skincare regimen

Conditions: Photodamaged Skin; Volume Deficiency of the Midface

Summary: to assess skin structural change in midface after treatment with a biostimulator using line-field optical coherence tomography

this is a randomized, double-blinded, split-face, comparative study. this study is designed to enroll and randomize approximately 20 subjects. all subjects are to have midface volume loss and contour deficiency and facial photodamage. eligible subjects are randomized to receive study skincare products for pre-conditioning, 2 weeks before baseline. all subjects receive biostimulator treatment at the midface by the treating investigator at baseline. the method of injection is at the discretion of the treating investigator. a sufficient amount of product is injected to achieve optimal correction of the midface, in the opinion of the treating investigator. at the 6-week visit, after all study procedures for the visit are completed, treated subjects received a second biostimulator treatment to achieve optimal aesthetic improvement. at the 12-week and 18-week visits, similar study procedures are performed.

Eligibility criteria:
inclusion criteria: * subjects diagnosed with symmetrical, moderate-to-severe cheek wrinkles on each side of the face as assessed via the galderma cheek wrinkles scale. * subjects with symmetrical, mild-to-severe photodamage at both sides of the midface. * subject who in the opinion of the treating investigator would need 2 biostimulator treatments for optimal clinical outcomes. * ability of giving consent for participation in the study. * agreement to adhere to the procedures and requirements of the study and to report to the institute on the day(s) and at the time(s) scheduled for the assessments. exclusion criteria: * subjects with asymmetrical severity or unidentical cheek wrinkle score between 2 sides of the cheek. * asymmetrical severity photodamage score between 2 sides of the midface. * subjects with a history of allergy or hypersensitivity to any ingredient of the treatment products. * previous tissue-augmenting therapy, contouring, or revitalization treatment in the face, except lips. * previous treatment/procedure in the face in the previous 6 months that, in the investigator's opinion, would interfere with the study injections and/or study assessments or exposed the study subject to undue risk by study participation, or planning to undergo any of these procedures affecting the treatment area at any time during the study. * subjects with any medical condition that, in the opinion of the investigator, would make the subject unsuitable for inclusion.
french register of duodenal adenomas characterization and evaluation of endoscopic mucosectomy

Conditions: Duodenal Adenoma

Summary: sporadic duodenal adenomas are rare. as they are highly pre neoplastic, they should be removed and endoscopic mucosectomy is recommended during digestive endoscopy. however, this technique, albeit less dangerous than surgery, is associated with complications such as haemorrhages, perforations, and more relapse than that can be observed for colorectal adenomas. as no prospective data have been published this french multicenter study aim to analyze results of this technique under standardized and secured procedure. all investigators are expert in therapeutic endoscopy in tertiary centers and are member of a group of clinical researcher involved in that field (" graphe " (groupe de recherche et d'action des praticiens hospitaliers en endoscopie interventionnelle). results are highly expected among the international society of gastroenterologists who need to confirm the efficacy of endoscopy and define optimal conditions for performing adenomas resection in this location primary end point is the two years recurrence rate. secondary end points are frequency and type of complication after standardized endoscopic mucosectomy of duodenal adenomas, frequency and type of complications after a second endoscopic mucosectomy and patient's characteristics patients with sporadic duodenal adenomas larger than 5 mm requiring endoscopic mucosectomy will be included. non-inclusion criteria concern patients with previous endoscopic resection, lesion involving the major papilla, sub mucosal lesions, familial adenomatous polyposis and use of antiplatelet agent during the five last days. hundred and twenty patients will be included and followed 2 years after mucosectomy.


Eligibility criteria:
inclusion criteria: * patients with sporadic duodenal adenomas larger than 5 mm requiring endoscopic mucosectomy exclusion criteria: * patients with previous endoscopic resection, * patients prsenting lesion involving the major papilla, sub mucosal lesions * patient with familial adenomatous polyposis * patient undergoing use of antiplatelet agent during the five last days
neurological outcome after erythropoietin treatment for neonatal encephalopathy

Conditions: Hypoxic-Ischemic Encephalopathy

Summary: perinatal asphyxia-induced brain injury is one of the most common causes of morbidity and mortality in term and preterm neonates, accounting for 23% of neonatal deaths globally. although many neuroprotective strategies appeared promising in animal models, most of them have failed clinically. erythropoietin (epo) is an endogenous cytokine originally identified for its role in erythropoiesis. clinical trial has demonstrated the safety and efficacy of recombinant human erythropoietin (r-hu-epo) in the prevention or treatment of anemia of prematurity. to date, there are no reports evaluating possible effects of epo on neonatal hie.

hypoxic-ischemic encephalopathy of the newborn infant remains a significant socio-economic health problem worldwide. moderate to severe hie of newborn infants is associated with a high rate of death or long-term disabilities. historically, treatment has been purely supportive including stabilizing cardio-respiratory functions and treating convulsions.recent multi-center trials assessing the effects of hypothermia demonstrated improved outcome in term neonates with moderate hypoxic-ischemic encephalopathy (hie). however, hypothermia was not effective beyond 6 hrs after brain injury. systemically administered epo was neuroprotective in neonatal brain injury models. clinical study on adult stroke showed improved outcome. however, treating hie with epo raises a series of questions such as: i) can the patient population of this study readily be compared with those in the hypothermia trials? ii) what are the pharmacokinetics of epo, including issues of dosage and timing, and does administered epo cross the blood-brain-barrier? iii) how does the effectiveness, side effects and potentials of epo therapy compare with induced hypothermia?

Eligibility criteria:
inclusion criteria: * apgar score of 5 or less at 5 min after birth or continued need for resuscitation, including endotracheal or mask ventilation at 10 min after birth. * the severity of encephalopathy, moderate or severe, was assessed by certified examiners according to the criteria of sarnat and sarnat(13), consisting of altered state of consciousness: lethargy, stupor or coma, and at least one or more of hypotonia, abnormal reflexes including oculomotor or pupillary abnormalities, absent or weak sucking or clinical seizures. exclusion criteria: * major congenital abnormalities, head trauma or skull fracture causing major intracranial hemorrhage, mild hie, financial problems of the parents, lack of permanent address or postnatal age \> 48 hrs

Keywords: asphyxia erythropoietin neonates
observational study of canadian patients (6 years or older) receiving dupixent® for moderate to severe atopic dermatitis

Conditions: Moderate to Severe Atopic Dermatitis

Summary: this is a prospective, 18-month observational study of adult, adolescent and pediatric canadian participants with atopic dermatitis (ad) commonly known as eczema, who receive treatment with dupixent for moderate-to-severe ad (msad) according to the canadian-specific prescribing information (in accordance with the canadian dupixent product monograph). the study will be conducted in approximately 30 centers in canada to assess participants of all ethnicities and races. at each participating site, all ad participants who receive an initial prescription for dupixent will be invited to participate in this study, until the canadian enrollment goal is achieved.

the duration of the study for each participant will be of 18 months.

Eligibility criteria:
inclusion criteria: * male or female, 6 years or older at baseline visit (canada has received the country's regulatory approval for use of dupixent treating msad for these ages). * participant is initiating dupilumab as part of routine clinical care through the dupixent patient support program (psp) for the treatment of msad, as per reimbursement criteria. decision to treat with dupilumab must have been reached prior to and independently of recruitment in the study. * have a physician's diagnosis of msad. * provided signed informed consent or parental/legally acceptable representative consent and/or participant assent. during the study, subjects will continue to receive maintenance therapies for their ad as clinically indicated and as per usual medical practice. * participant or parental representative able to understand english and/or canadian french to complete study-related questionnaires. exclusion criteria: * participants who have a contraindication to the drug according to the canadian-specific prescribing information label. * any condition that, in the opinion of the investigator, may interfere with participant's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the participant from adequately completing the schedule of visits and assessments. * participants currently participating in any interventional clinical trial which modifies participant care. * prior use of dupixent within 6 months of the baseline visit. * participants not willing to sign the informed consent form.
a safety and dose-finding study of synt001 in subjects with pemphigus (vulgaris or foliaceus)

Conditions: Pemphigus; Pemphigus Vulgaris; Pemphigus Foliaceus

Summary: this was a multicenter, open-label safety study to determine the dose regimen of synt001 (alxn1830) administered intravenously in participants with pemphigus (vulgaris or foliaceus).

this study planned to evaluate 2 cohorts: up to 8 participants to receive 5 weekly intravenous (iv) doses of alxn1830 at 10 milligram/kilogram (mg/kg) (cohort 1) and up to 12 participants to receive 3 x 30 mg/kg weekly doses of alxn1830 iv (loading) followed by 5 x 10 mg/kg doses of alxn1830 iv every other week or 10 weekly doses of alxn1830 iv (maintenance) (cohort 2). this study was terminated after the safety, tolerability, pharmacokinetics (pk), pharmacodynamics (pd), and efficacy were characterized in participants with pemphigus at a single dose level (10 mg/kg) in cohort 1, before any participants were enrolled in cohort 2. the study consisted of 3 periods: screening, treatment, and follow-up.

Eligibility criteria:
inclusion criteria: participants must have meet the following criteria to be included: * were willing and able to read, understand and sign an informed consent form * documented diagnosis of pemphigus vulgaris or foliaceus * were required to use medically acceptable contraception exclusion criteria: participants meeting any of the following criteria were excluded: * were unable or unwilling to comply with the protocol * active non-hematologic malignancy or history of non-hematologic malignancy in the 3 years prior to screening (exclusive of non-melanoma skin cancer and cervical cancer in situ) * positive for human immunodeficiency virus (hiv) or hepatitis c antibody * positive for hepatitis b surface antigen * iv immunoglobulin treatment within 30 days of screening * any exposure to an investigational drug or device within the 30 days prior to screening * plasmapheresis or immunoadsorption within 30 days of screening * participant had any current medical condition that, in the opinion of the investigator, may have compromised their safety or compliance, preclude successful conduct of the study, or interfere with interpretation of the results
postoperative pain after total laparoscopic hysterectomy: a comparison of single-port and three-port laparoscopy

Conditions: Uterine Disease; Postoperative Pain

Summary: the objective of this study is to compare postoperative pain between single-port access total laparoscopic hysterectomy (spa-tlh) using a transumbilical single-port system and conventional multi (three)-port access total laparoscopic hysterectomy (mpa-tlh). a prospective study was conducted on women who underwent spa-tlh and mpa-tlh for benign gynecologic diseases from march 2014 through january 2015. the study enrolled 60 patients and postoperative pain and operative outcomes were examined.

the randomization code was inserted into numbered and sealed envelopes. a single envelope was opened when the patient was arrived in operating room. all patients gave their informed consent for the study and underwent hysterectomy for benign diseases. after surgery, in all patients, three sticking plasters were applied by the same manner with three port surgery group therefore not only patients but also anesthesiology staff who measure the pain score could not know the type of surgery until data collection was finished. pain was assessed according to the visual analog scale (vas) (0 = no pain; 10 = worst pain imaginable). patients were asked to evaluate the maximal degree of pain. pain scores were recorded at least at 30 minutes, 1, 12, 24 and 48 hours after surgery. postoperative pain was measured by two independent anesthesiology staff members for cross-checking. in order to compare the intensity of postoperative pain accurately, all the participants had anesthesia in the same way and postoperative pain was managed by fentanyl-based intravenous patient-controlled analgesia pump (iv-pca, baxter healthcare corporation, u.s.a: bolus dose 0.12mg/kg of fentanyl, lockout interval of 5 min, basal infusion 0.02ml/kg) with the same regimen on both groups. a patient was instructed to press the iv-pca bolus button when the vas was 3 or higher. a patient under iv-pca whose vas was over 5 received 50mg of tridol injection intravenously. iv-pca was removed 48 hours after surgery unless a patient specially asked it. then, using log data downloaded by a program, we analyzed the number of iv-pca bolus requests by time interval, total amount of fentanyl consumption, and the number of additional tridol administration and injection time.

Eligibility criteria:
incluson criteria 1. subject has benign uterine disease 2. subject needs total hysterectomy. 3. subject has appropriate medical status for laparoscopic surgery (american society of anesthesiologists physical status classification system 1-3). exclusion criteria: 1. suspicion of malignancy 2. the need for simultaneous interventions such as prolapse repair 3. uterine size greater than 18 weeks of gestation 4. ongoing peritoneal dialysis 5. diseases associated with abdominal pain such as pancreatitis

Keywords: postoperative pain hysterectomy single-port access laparoscopy multi-port access laparoscopy tlh
vastus medialis activation during mcmurray's test

Conditions: Electromyography; Knee Injuries; Knee Pain Chronic

Summary: this study will use electromyography to evaluate activation patterns of the vastus medialis and vastus lateralis muscles during the mcmurray's knee examination test in different knee positions.

the mcmurray test is commonly used to assess knee pathology. however, it is unclear which knee position during this test best isolates activity of the vastus medialis muscle. this study will measure vastus medialis and lateralis activation using surface electromyography in 30 healthy participants performing the mcmurray test. different knee flexion and rotation angles will be evaluated to determine which position optimally activates the vastus medialis. results may enhance utilization of the mcmurray test in rehabilitation programs targeting this muscle.

Eligibility criteria:
inclusion criteria: * healthy adults aged 18-45 years * no history of knee pathology exclusion criteria: * contraindications to emg * neurological or muscular disorders
the optimizing treatment of pegifn alfa in hbeag-negative chb patients with low level hbsag

Conditions: Chronic Hepatitis B

Summary: as hbsag clearance is uncommon in chronic hepatitis b (chb) patients on nucleoside analogues (nas) therapy. the purpose of this study is to optimize hbsag clearance in chb patients with sequential treatment of pegylated interferon alpha and nas.

in order to optimize hbsag clearance in chb patients with low level hbsag, the investigators enrolled patients who had received, and responded to, nas for more than 12 months(see the inclusion criteria), and patients are switched to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 48 weeks and follow up for 24 weeks.

Eligibility criteria:
inclusion criteria: 1. chb patients who had received nas for more than 12 months. 2. hepatitis b e antigen (hbeag)-negative and anti-hbeag positive. 3. hepatitis b surface antigen (hbsag) positive and \<1500 iu/ml. 4. hepatitis b virus dna not detectable(roche cobas). exclusion criteria: 1. patients with liver cirrhosis, hepatocellular carcinoma or other malignancies. 2. patients with other factors causing liver diseases. 3. pregnant and lactating women. 4. patients with concomitant hiv infection or congenital immune deficiency diseases. 5. patients with diabetes, autoimmune diseases. 6. patients with important organ dysfunctions. 7. patients with serious complications (e.g., infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding.) 8. patients who receive antineoplastic or immunomodulatory therapy in the past 12 months. 9. patients who can't come back to clinic for follow-up on schedule.

Keywords: chronic hepatitis b peginterferon alfa
blue note therapeutics product bnt 103 usability and user engagement

Conditions: Breast Cancer Female

Summary: this test aims to explore product development-focused usability and user engagement.

sponsor is testing an innovative peer-to-peer communication tool during this trial.

Eligibility criteria:
inclusion criteria: * patient can read, write, and speak in english * patient is between the ages of 35-55 * diagnosed with stage i-iii breast cancer * in active treatment or within 3 months of ending active treatment and under the care of a clinician at time of study * apple mobile phone or tablet user * willing to participate in study protocol exclusion criteria: * any participant not meeting inclusion criteria